Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply on Monday. Mereo BioPharma and its partner Ultragenyx revealed results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). Osteogenesis Imperfecta (OI) includes a group of genetic…
Continue reading...